Skip to content
Triangle logo TriangleGet started
← Study library

NCT00022659 · CITED IN SOURCE DOCUMENTS

Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2019-07-24

This phase II trial is to see if bevacizumab works in treating patients who have persistent or recurrent ovarian epithelial cancer or primary peritoneal cancer. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Progression-free Survival at 6 Months

→

outcome · POSTED

Tumor Response

→

outcome · POSTED

Number of Participants and Degree of Toxicity of Bevacizumab in This Cohort of Patients as Assessed by CTC.

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Duration of Progression-free Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Histologically confirmed ovarian epithelial or primary peritoneal carcinoma * Recurrent or persistent after initial standard surgery or chemotherapy * Incurable with standard surgery, chemotherapy, or radiotherapy * At least 1 unidimensionally measurable target lesion * At least 20 mm by conventional techniques * At least 10 mm by spiral CT scan * Outside the area of prior radiotherapy * Accessible to guided core needle biopsy * Received 1 prior platinum-based chemotherapy regimen (e.g., carboplatin, cisplatin, or another organoplatinum compound) for primary disease * May have included high-dose therapy, consolidation, or extended therapy administered after surgical or non-surgical assessment * Patients with only 1 prior platinum-based chemotherapy regimen must have an initial treatment-free interval of less than 12 months * Patients with an initial treatment-free interval of more than 12 months must have progressive disease after prior platinum-based chemotherapy regimen as second-line therapy * No tumors involving major blood vessels * No evidence of CNS disease (primary brain tumor or brain metastases) within the past 5 years * Ineligible for higher priority Gynecologic Oncology Group (GOG) protocols (i.e., active phase III GOG protocols for the same patient population) * Performance status - GOG 0-2 (patients who have received 1 prior regimen) * Performance status - GOG 0-1 (patients who have received 2 prior regimens) * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * No known bleeding disorder or coagulopathy * No active bleeding * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * serum glutamate oxaloacetate transaminase (SGOT) ≤ 2.5 times ULN * Alkaline phosphatase ≤ 2.5 times ULN * PT (INR) ≤ 1.5 (INR 2-3 if on stable dose of therapeutic warfarin or low molecular weight heparin) * Partial thromboplastin time (PTT) \< 1.2 times control * Creatinine ≤ 1.5 times ULN * Creatinine clearance \> 60 mL/min * No proteinuria, as indicated by 1 of the following: * Negative urine dipstick * Urine protein \< 30 mg/dL * Urine protein \< 1,000 mg on 24-hour urine collection * No clinically significant cardiovascular disease, including any of the following: * Uncontrolled hypertension * Myocardial infarction within the past 6 months * Unstable angina within the past 6 months * New York Heart Association class II-IV congestive heart failure * Serious cardiac arrhythmia requiring medication * Peripheral vascular disease ≥ grade 2 * No stroke within the past 5 years * No pathologic condition that carries a high risk of bleeding * No significant traumatic injury within the past 28 days * No other invasive malignancy within the past 5 years except nonmelanoma skin cancer * No uncontrolled seizures within the past 5 years * No neuropathy (motor and sensory) ≥ grade 2 * No serious non-healing wound, ulcer, or bone fracture * No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies * No active infection requiring parenteral antibiotics * No known claustrophobia that would preclude MRI tolerance * No ferromagnetic implants or pacers * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for at least 3 months after study treatment * At least 3 weeks since prior immunologic therapy directed at malignancy * No prior bevacizumab * No other concurrent immunotherapy directed at malignancy * One additional prior cytotoxic regimen for recurrent or persistent disease allowed * No prior non-cytotoxic chemotherapy for recurrent or persistent disease * No concurrent chemotherapy directed at malignancy * At least 1 week since prior hormonal therapy directed at malignancy * No concurrent hormonal therapy directed at malignancy * Concurrent hormone replacement therapy allowed * Recovered from prior radiotherapy * No concurrent radiotherapy directed at malignancy * At least 28 days since prior major surgery or open biopsy and recovered * At least 7 days since prior core biopsy or placement of vascular access device * No anticipated need for major surgical procedure during study participation * At least 3 weeks since other prior therapy directed at malignancy * No prior anticancer therapy that would preclude study entry
healthy Volunteers
false
minimum Age
18 Years
sex
FEMALE
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Biological: bevacizumab
    2. Other: laboratory biomarker analysis
    label
    Treatment (bevacizumab)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment (bevacizumab)
    description
    Given IV
    name
    bevacizumab
    other Names
    1. anti-VEGF humanized monoclonal antibody
    2. anti-VEGF monoclonal antibody
    3. Avastin
    4. rhuMAb VEGF
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Treatment (bevacizumab)
    description
    Correlative studies
    name
    laboratory biomarker analysis
    type
    OTHER
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
64
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Progression is defined according to RECIST v1.0 as at least a 20% increase in the sum of LD target lesions taking as reference the smallest sum LD recorded since study entry, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, global deterioration in health status attributable to the disease requiring a change in therapy without objective evidence of progression, or unequivocal progression of existing non-target lesions.
    measure
    Progression-free Survival at 6 Months
    time Frame
    Every other cycle for 6 months.
  2. description
    RECIST 1.0 defines complete response as the disappearance of all target lesions and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart. Partial response is defined as at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be no unequivocal progression of non-target lesions and no new lesions. Documentation by two disease assessments at least 4 weeks apart is required. In the case where the ONLY target lesion is a solitary pelvic mass measured by physical exam, which is not radiographically measurable, a 50% decrease in the LD is required. These patients will have their response classified according to the definitions stated above. Complete and partial responses are included in the objective tumor response rate.
    measure
    Tumor Response
    time Frame
    Every other cycle for the first 6 months; then every 3 months x 2 ; then every 6 months thereafter for up to 5 years.
  3. measure
    Number of Participants and Degree of Toxicity of Bevacizumab in This Cohort of Patients as Assessed by CTC.
    time Frame
    Assessed every cycle while on treatment, 30 days after the last cycle of treatment, up to 5 years.
secondary Outcomes
  1. description
    The observed length of life from entry into the study to death or the date of last contact.
    measure
    Overall Survival
    time Frame
    From study entry to death or last contact, up to 5 years.
  2. description
    Progression is defined according to RECIST v1.0 as at least a 20% increase in the sum of LD target lesions taking as reference the smallest sum LD recorded since study entry, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, global deterioration in health status attributable to the disease requiring a change in therapy without objective evidence of progression, or unequivocal progression of existing non-target lesions.
    measure
    Duration of Progression-free Survival
    time Frame
    Every other cycle for the first 6 months; then every 3 months x 2 ; then every 6 months therafter for up to 5 years.
Full study description
brief Summary
This phase II trial is to see if bevacizumab works in treating patients who have persistent or recurrent ovarian epithelial cancer or primary peritoneal cancer. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them.
detailed Description
PRIMARY OBJECTIVES: I. Determine the 6-month progression-free survival of patients with persistent or recurrent ovarian epithelial or primary peritoneal cancer treated with bevacizumab. II. Determine the nature and degree of toxicity of this drug in these patients. III. Determine the progression-free and overall survival of patients treated with this drug. IV. Determine the frequency of clinical response in patients treated with this drug. V. Determine the effect of this drug on initial performance status, age, and mucinous or clear cell histology in these patients. VI. Correlate biological and imaging markers with 6-month progression-free survival of patients treated with this drug. OUTLINE: This is a multicenter study. Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-a46006dab698c43ced18
      requested nct id
      NCT00022659
      primary nct id
      NCT00022659
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      d626fa717739cf3dda8aebd26e3ffaf109ec1e006da0173aee8007b288898b2c
      payload sha256
      11133cda92d321cf75624a1398395ebb576fa3d110c11ffb7be3824923ec5c46
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-a46006dab698c43ced18
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00022659
      occurrences
      1. context exact
        is antibody to vascular endothelial growth factor.</p> <div class="pdq-content-list"><ol id="_1100"><li>The first study (<a href="/clinicaltrials/NCT00022659">GOG-0170D</a>) included 62 patients who had received only one or two previous treatments. These last patients had received one additional platinum-based reg
        end
        317791
        exact text
        NCT00022659
        start
        317780
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/ff9ceeeae0fbdc33fd.html
      source file sha256
      d626fa717739cf3dda8aebd26e3ffaf109ec1e006da0173aee8007b288898b2c
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:22:10.059252+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      2a71979c192f62071168507c9e3b23e31a4e8fe2e21ca0f7ee294555ff0250c9
      source title
      Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: May 14, 2025
        datetime
        2025-05-14T12:00:00Z
        display
        May 14, 2025

    Preserved source evidence · Not medical advice